>
A $2 million drug is about to hit the market
May 8, 2019

From the Wall Street Journal:

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Novartis has yet to set a price for the gene therapy called Zolgensma, but executives say the drug's potential to cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two, justifies a seven-figure price.

Gene therapies target diseases that result from a faulty gene by introducing a working version into the body. They are attracting interest, both for their ability to cure otherwise devastating illnesses in one treatment and also for their high cost. Luxturna, the only gene therapy on sale in the U.S. so far to treat a form of inherited sight loss, costs $850,000 a patient.

Continue reading at the Wall Street Journal...

You may also like

Millions should stop taking aspirin for heart health

"Millions of people who take aspirin to prevent a heart attack may need to rethink the pill-popping."

New federal data help pinpoint the opioid epidemic

"Over that seven-year period, 76 billion pills were distributed in all."

Study shows a correlation between screen time and depression in teens

"An increase of as little as one hour of social media interaction from normal levels would result in a measurable increase in depression, the study found."